Welcome to our dedicated page for Thorne Healthtech news (Ticker: THRN), a resource for investors and traders seeking the latest updates and insights on Thorne Healthtech stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Thorne Healthtech's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Thorne Healthtech's position in the market.
Thorne HealthTech (NASDAQ: THRN) has achieved self-affirmed GRAS (Generally Recognized as Safe) status for its proprietary nicotinamide riboside malate (NRM) product. This designation confirms that NRM meets safety standards based on extensive testing and expert review. Thorne’s NRM product suite, including NiaCel® and ResveraCel®, is also NSF Certified for Sport®, ensuring quality and safety. CEO Paul Jacobson emphasized that this GRAS status reinforces the product's quality, safety, and efficacy in stimulating energy production through NAD+.
Thorne HealthTech (NASDAQ: THRN) will announce its Q2 2022 financial results after market close on August 9, 2022, followed by a conference call on August 10, 2022, at 8 a.m. ET. Investors can access the call through their website. A replay will also be available for seven days. Thorne is focused on personalized health solutions, relying on testing and data to enhance product efficacy.
Thorne HealthTech (NASDAQ: THRN) has been named the Exclusive Supplement Supplier for the U.S. National Team by USRowing for 2022-2024. This partnership aims to enhance athlete performance through high-quality, NSF Certified for Sport nutritional supplements. USRowing CEO Amanda Kraus praised Thorne's reputation and approach to wellness, aligning with their values of excellence and safety. Thorne CEO Paul Jacobson highlighted the importance of personalized health solutions for athletes. This partnership demonstrates Thorne's ongoing commitment to supporting U.S. National teams in achieving their performance goals.
Thorne HealthTech has revamped its Gut Health Test by introducing the Microbiome Wipe, a first-to-market solution that simplifies microbiome testing. This innovative wipe replaces traditional stool samples, enhancing user experience and encouraging more individuals to participate in gut health testing. Clinical studies suggest that the Microbiome Wipe demonstrates increased efficacy compared to standard methods. Thorne aims to empower users with personalized data to improve overall health and wellness.
Thorne HealthTech (NASDAQ: THRN) reported a strong first quarter for 2022, with net sales increasing by 22.9% to $54.7 million, driven by a 33.0% rise in direct-to-consumer sales. Gross profit rose 29.6% to $30.1 million, with a gross margin of 55.1%. The company announced a net income of $5.0 million and reaffirmed its full-year 2022 guidance, expecting net sales of $240 million to $250 million. Active subscriptions grew by 57.0% to approximately 265,000.
Thorne HealthTech (NASDAQ: THRN) reported promising results from a surveillance study conducted by the Medical Research Council Epidemiology Unit at the University of Cambridge. The study involved 4,000 participants who successfully collected over 10,000 blood samples using the OneDraw™ Blood Collection Device, achieving a success rate of 99.9%. The device allows painless self-administration of blood samples and shows potential for expanding telehealth services. Results indicating high participant acceptability were published in the Journal of Telemedicine and Telecare on May 10, 2022.
Fullscript has expanded its offerings to include Thorne HealthTech (NASDAQ: THRN), allowing practitioners to access Thorne's scientifically-backed wellness products. This partnership aims to enhance patient health and wellness by providing high-quality nutritional supplements. Thorne collaborates with Mayo Clinic on wellness research, ensuring the efficacy of its products, which are trusted by over four million customers and 45,000 health professionals. The collaboration underscores a commitment to supporting integrative medicine and personalized health solutions.
On April 6, 2022, Thorne HealthTech (NASDAQ: THRN) was announced as USA Boxing's official performance nutrition partner for 2022. Thorne will provide its NSF Certified for Sport® product line to enhance the performance of USA Boxing's national teams. Members can purchase Thorne products at a discounted rate. The NSF program ensures safety and integrity in nutritional supplements. Thorne is trusted by numerous U.S. National teams and focuses on personalized health solutions.
Thorne HealthTech (NASDAQ: THRN) launched its Healthy Aging campaign on March 28, 2022, partnering with former NFL player Greg Olsen. The campaign promotes a personalized approach to well-being through nutritional supplements and scientific testing. Thorne's products—Collagen Plus, NiaCel®, and ResveraCel®—contain nicotinamide riboside to support cellular health, exercise, and metabolism. Running until June 19, 2022, the campaign will include online ads and influencer marketing. Olsen will also donate proceeds to his charity, HEARTest Yard, aiding families of children with congenital heart disease.
Thorne HealthTech (THRN) reported a strong performance for Q4 and the full year 2021, with net sales increasing by 37.8% to $49.9 million in Q4 and 33.8% to $185.2 million for the year. Direct-to-consumer sales surged 56.1% in Q4. Gross profit also rose significantly, reaching $25.7 million in Q4 and $97.4 million for the full year. The company expects 2022 net sales of $240-$250 million and adjusted EBITDA of $30-$35 million. Notably, active subscriptions grew 65.5% year-over-year, indicating a solid market position.
